「T-CELL」の共起表現一覧(1語右で並び替え)
該当件数 : 75件
Thus pimecrolimus inhibits | T-cell activation by inhibiting the synthesis and rel |
nd T cells encounters a programmed change upon | T-cell activation, which predominantly produces full- |
are also widely accepted as the initiators of | T-cell activation. |
hysiologic ligand-receptor complex involved in | T-cell activation. |
bition of B7-CTLA-4-mediated downregulation of | T-cell activation; subsequently, B7.1 or B7.2 may int |
Nelarabine is a chemotherapy drug used in | T-cell acute lymphoblastic leukemia. |
n October 2005, it was approved by the FDA for | T-cell acute lymphoblastic leukemia and T-cell lympho |
Increasing | T-cell age reduces effector activity but preserves pr |
iagnosed with lymphoblastic leukemia/lymphoma ( | T-cell ALL), a complex form of cancer targeting the l |
amily that is also called Interferon-inducible | T-cell alpha chemoattractant (I-TAC) and Interferon-g |
ant developmental signals from IL-7 and IL-15, | T-cell and NK cell populations respectively fail to d |
it is known to be a key effector molecule for | T-cell- and natural killer-cell-mediated cytolysis. |
n tyrosine kinases following activation of the | T-cell antigen receptor (TCR) signal transduction pat |
ins spontaneously distatch from the TCR of the | T-cell, because of weak binding affinities (monomeric |
structure of CD28 was obtained in 2005 by the | T-cell biology group at the University of Oxford. |
CXCL9 is a | T-cell chemoattractant, which is induced by IFN-γ. |
He showed that the | T-cell co-receptors CD4 (also the receptor for the hu |
Inducible | T-cell costimulator is a protein that in humans is en |
ndent manner, indicating that gliadin specific | T-cell could present these antigens to the immune sys |
with ionomycin, can also be used to stimulate | T-cell cytokine production, and is used in protocols |
fic function in the mechanism or regulation of | T-cell cytolytic activity. |
results in a cascade of signals important for | T-cell development within the thymus and survival wit |
L-7 receptor exhibit thymic atrophy, arrest of | T-cell development at the double positive stage, and |
ntibody, chemically linked Fab and bi-specific | T-cell engager (bottom row). |
Bi-specific | T-cell engagers employ a smilar mechanism of action w |
r NF-kappaB, and on development of bi-specific | T-cell engagers for therapy of cancer. |
nce, showing the overlapping of 3 varieties of | T-cell epitope. |
g this bond transglutaminase becomes linked to | T-cell epitopes on gliadin. |
stable in human blood serum and do not contain | T-cell epitopes. |
-6 causes an IL-10-dependent inhibition of CD4 | T-cell expansion and function by up-regulating PD-1 l |
TA causes an IL-10-dependent inhibition of CD4 | T-cell expansion and function by up-regulating PD-1 l |
This receptor can activate | T-cell factor signaling. |
BTLA-HVEM complexes negatively regulate | T-cell immune responses. |
iology at Yale School of Medicine, focusing on | T-cell immunity in West Nile Virus, publishing severa |
ding of the intracellular signals that control | T-cell immunity. |
mutation in this gene has been correlated with | T-cell immunodeficiency, the skin disorder congenital |
loepiphyseal dysplasia, renal dysfunction, and | T-cell immunodeficiency. |
However, unlike PD-1 and CTLA-4, BTLA displays | T-Cell inhibition via interaction with tumor necrosis |
here it appears to mediate aspects of B-cell - | T-cell interaction. |
This technology combines a current | T-cell isolation method with the Strep-tag technology |
ing HTLV-I induced diseases like ATL the adult | T-cell leukemia and HMS/TSP like neurological disorde |
viruses, initially as a means of understanding | T-cell leukemia and other cancers, which may be cause |
roto-oncogene implicated in the development of | T-Cell Leukemias. |
ed by CD34+ acute myeloid leukemia cell lines, | T-cell lines, activated T lymphoblasts, endothelial c |
II trials for multiple myeloma and peripheral | T-cell lymphoma are still recruiting. |
, he was diagnosed with enteropathy-associated | T-cell lymphoma in January 2009 and died on 24 June 2 |
dministration (FDA) for treatment of Cutaneous | T-cell lymphoma (CTCL). |
tment of cutaneous manifestations of cutaneous | T-cell lymphoma in patients who are refractory to at |
on from the FDA for the treatment of cutaneous | T-cell lymphoma, and orphan drug status from the FDA |
inent in a rare cancer, enteropathy associated | T-cell lymphoma. |
Hence, expression of CXCL13 in | T-cell lymphomas, such as Angioimmunoblastic T-cell L |
in reference to the Tax1 protein of the Human | T-cell Lymphotropic Virus (HTLV)which was used to dis |
found the drug caused many stage IV cutaneous | T-cell lympomas to regress or stabilize extending pat |
CD5 was used as a | T-cell marker until monoclonal antibodies against CD3 |
sis fungoides, but is frequently lost in other | T-cell neoplasms. |
stablishing a specific interaction between the | T-cell of interest and a molecule that is conjugated |
The gene is expressed in B-cell but not | T-cell or myeloid cell lines. |
Temporary depletion of the | T-cell population at the time of the transplant also |
mily with strong homology to the Suppressor of | T-cell receptor signaling-1 (Sts-1 PGM) protein. |
ity hypothesis states that the affinity of the | T-cell receptor for the MHC:peptide complex and the d |
T-cell receptor zeta, together with T-cell receptor a | |
transmit signals from the B-Cell receptor and | T-Cell receptor. |
ith a Tyrosine phosphorylated Peptide from the | T-cell Receptor. |
unoglobulin light and heavy chains; in several | T-cell receptors such as CD2 (Cluster of Differentiat |
It also supports signaling from | T-cell receptors. |
ass I and II complex molecules, and in various | T-cell receptors. |
o diagnose SCID in newborns through the use of | T-cell recombinant excision circles. |
may offer new strategies in clinical and basic | T-cell research. |
They are activated and control | T-cell responses to foreign pathogens, transplants an |
For the | T-cell signal, see T helper cell#Verification (Signal |
T-cell surface glycoprotein CD3 zeta chain also known | |
T-cell surface glycoprotein CD1e, membrane-associated | |
It has also been called | T-cell surface antigen T11/Leu-5, LFA-2, LFA-3 recept |
T-cell surface antigen CD2 IPR013285 | |
as to be custom made for each antigen specific | t-cell that one desires to detect. |
こんにちは ゲスト さん
ログイン |
Weblio会員(無料)になると 検索履歴を保存できる! 語彙力診断の実施回数増加! |
こんにちは ゲスト さん
ログイン |
Weblio会員(無料)になると 検索履歴を保存できる! 語彙力診断の実施回数増加! |